SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-188223
Filing Date
2023-07-17
Accepted
2023-07-17 17:29:28
Documents
18
Period of Report
2023-07-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d510291d8k.htm   iXBRL 8-K 27044
2 EX-99.1 d510291dex991.htm EX-99.1 4544
3 EX-99.2 d510291dex992.htm EX-99.2 9955
7 GRAPHIC g510291g0717125446980.jpg GRAPHIC 2308
8 GRAPHIC g510291g0717125447272.jpg GRAPHIC 1511
9 GRAPHIC g510291g0717125447656.jpg GRAPHIC 1383
10 GRAPHIC g510291g0717131904614.jpg GRAPHIC 3147
  Complete submission text file 0001193125-23-188223.txt   185078

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ikt-20230717.xsd EX-101.SCH 2856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ikt-20230717_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ikt-20230717_pre.xml EX-101.PRE 11712
12 EXTRACTED XBRL INSTANCE DOCUMENT d510291d8k_htm.xml XML 3469
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39676 | Film No.: 231092477
SIC: 2836 Biological Products, (No Diagnostic Substances)